Prognostic Factors of Extramammary Paget’s Disease

[1]  J. Inthout,et al.  Associated malignancies in vulvar Paget disease , 2018, British Journal of Dermatology.

[2]  Zhong Wang,et al.  Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites , 2018, BMC Cancer.

[3]  T. Funakoshi,et al.  Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach , 2018, Front. Oncol..

[4]  T. Yamashita,et al.  Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease , 2017, Journal of dermatology (Print).

[5]  Jinhua Xu,et al.  Genetic Analysis of Mismatch Repair Genes Alterations in Extramammary Paget Disease , 2016, The American journal of surgical pathology.

[6]  Y. Fujisawa,et al.  A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors. , 2016, Journal of dermatological science.

[7]  Y. Kiyohara,et al.  Usefulness of sentinel lymph node biopsy for prognostic prediction in extramammary Paget’s disease , 2016, European Journal of Dermatology.

[8]  I. Zapardiel,et al.  Prognostic factors for recurrence and survival among patients with invasive vulvar Paget disease included in the VULCAN study , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  Hong-Duo Chen,et al.  miR-31 is distinctively overexpressed in primary male extramammary Paget's disease , 2016, Oncotarget.

[10]  H. Shimizu,et al.  mTOR expression correlates with invasiveness and progression of extramammary Paget's disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  Y. Kong,et al.  Primary invasive extramammary Paget disease on penoscrotum: a clinicopathological analysis of 41 cases. , 2016, Human pathology.

[12]  M. Guan,et al.  Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients. , 2015, International journal of clinical and experimental pathology.

[13]  Y. Fujisawa,et al.  The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients. , 2015, Journal of dermatological science.

[14]  S. Granter,et al.  Risk stratification in extramammary Paget disease , 2015, Clinical and experimental dermatology.

[15]  Y. Oda,et al.  Tumor thickness as a prognostic factor in extramammary Paget's disease , 2015, The Journal of dermatology.

[16]  F. Lai,et al.  Significant male predisposition in extramammary Paget disease: a nationwide population‐based study in Taiwan , 2014, The British journal of dermatology.

[17]  H. Shimizu,et al.  MUC5AC expression correlates with invasiveness and progression of extramammary Paget's disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  H. Tsuda,et al.  Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease , 2013, The British journal of dermatology.

[19]  B. Meng-jun,et al.  Extramammary Paget's Disease of the Perianal Region: A Review of the Literature Emphasizing Management , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[20]  Yasuhiro Ito,et al.  Prognostic Indicators in 35 Patients with Extramammary Paget's Disease , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[21]  N. Zhang,et al.  PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease , 2012, Journal of cutaneous pathology.

[22]  Y. Fujisawa,et al.  Usefulness of sentinel lymph node biopsy for extramammary Paget disease , 2012, The British journal of dermatology.

[23]  M. Guan,et al.  Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease , 2012, Modern Pathology.

[24]  O. Dorigo,et al.  Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. , 2012, Gynecologic oncology.

[25]  Keith W. Jones,et al.  Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures , 2011, PloS one.

[26]  K. Cho,et al.  A multicenter study on extramammary Paget’s disease in Korea , 2011, International journal of dermatology.

[27]  Y. Moroi,et al.  Nerve growth factor, brain‐derived neurotrophic factor and their high‐affinity receptors are overexpressed in extramammary Paget's disease , 2010, Journal of cutaneous pathology.

[28]  C. Lam,et al.  Extramammary Paget's disease: Summary of current knowledge. , 2010, Dermatologic clinics.

[29]  X. Yao,et al.  Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget’s disease , 2009, The British journal of dermatology.

[30]  K. Urabe,et al.  Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget’s disease , 2008, Clinical and experimental dermatology.

[31]  J. Kim,et al.  Extramammary Paget’s disease in Korea: its association with gastrointestinal neoplasms , 2008, International Journal of Colorectal Disease.

[32]  M. Akiyama,et al.  High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease. , 2008, Journal of dermatological science.

[33]  K. Urabe,et al.  Concordant overexpression of p-FAK and p-ERK1/2 in extramammary Paget’s disease , 2008, Archives of Dermatological Research.

[34]  A. Fujimoto,et al.  Extramammary Paget’s disease: treatment, prognostic factors and outcome in 76 patients , 2007, The British journal of dermatology.

[35]  青柳 哲.  High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease , 2008 .

[36]  J. V. van Dijck,et al.  Epidemiology and treatment of extramammary Paget disease in the Netherlands. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  L. Horn,et al.  Mammary and extramammary Paget's disease: an immunohistochemical study of 83 cases , 2007, Histopathology.

[38]  A. Utani,et al.  Expression of prostate‐specific antigen and androgen receptor in extramammary Paget's disease and carcinoma , 2006, Clinical and experimental dermatology.

[39]  K. Urabe,et al.  Expression of insulin‐like growth factor‐1 receptor, p‐AKT and p‐ERK1/2 protein in extramammary Paget's disease , 2006, The British journal of dermatology.

[40]  H. Aburatani,et al.  Expression of phosphorylated Stat3, cyclin D1 and Bcl‐xL in extramammary Paget disease , 2006, The British journal of dermatology.

[41]  C. Miracco,et al.  Usefulness of CDX2 in the diagnosis of extramammary Paget disease associated with malignancies of intestinal type , 2005, The British journal of dermatology.

[42]  G. Ciaravino,et al.  Microinvasive Paget's disease. , 2004, Gynecologic oncology.

[43]  K. Yokoyama,et al.  Sentinel Lymph Node Biopsy in Patients with Extramammary Paget's Disease , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[44]  M. McCarter,et al.  Long-Term Outcome of Perianal Paget’s Disease , 2003, Diseases of the colon and rectum.

[45]  Yuhei Yamamoto,et al.  Indications for Lymph Node Dissection in the Treatment of Extramammary Paget's Disease , 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[46]  D. Finkelstein,et al.  Prognosis and management of extramammary Paget's disease and the association with secondary malignancies. , 2003, Journal of the American College of Surgeons.

[47]  K. Katada,et al.  Sentinel lymph node navigation surgery in Paget's disease of the vulva. , 2002, Clinical nuclear medicine.

[48]  S. Kitajima,et al.  Expression of mucin core proteins in extramammary Paget's disease , 2002, Pathology international.

[49]  Shinichi Watanabe,et al.  The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget’s disease , 2000, The British journal of dermatology.

[50]  M. Takata,et al.  erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease. , 1999, The Journal of investigative dermatology.

[51]  J. Goldblum,et al.  Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. , 1998, The American journal of surgical pathology.

[52]  J. Goldblum,et al.  Vulvar Paget's disease: a clinicopathologic and immunohistochemical study of 19 cases. , 1997, The American journal of surgical pathology.

[53]  D. Page,et al.  Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization of extramammary Paget's disease. , 1997, American journal of clinical pathology.

[54]  B. Fine,et al.  Minimally invasive Paget's disease of the vulva with extensive lymph node metastases. , 1995, Gynecologic oncology.

[55]  M. Shevchuk,et al.  Vulvar Paget's disease: the need to exclude an invasive lesion. , 1990, Gynecologic oncology.

[56]  J. J. Chanda.  Extramammary Paget's disease: prognosis and relationship to internal malignancy. , 1985, Journal of the American Academy of Dermatology.

[57]  M. Furue,et al.  Serum carcinoembryonic antigen level in Paget's disease , 1984, The British journal of dermatology.